Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 3Recruiting 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1Muscle Weakness 1Autoimmune Diseases 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × telitacicept × Clear all
NCT05737160 2025-05-23

Study of Telitacicept in Generalized Myasthenia Gravis

RemeGen Co., Ltd.

Phase 3 Completed
114 enrolled

Autoimmune Diseases, Myasthenia Gravis, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡